Fig. 2.

Brivaracetam and lacosamide treatments exerted an anti-proliferative effect and a reduction in migration ability of glioma cells. a Distribution of T98G cells in the different phases of the cell cycle upon 24 h BRV or LCM treatments (IC20). Data are expressed as percentage of cell in a specific phase (G0/G1, S, G2/M) and refers to at least four independent experiments. Statistical evaluation was performed by the student’s t-test. Histogram bars represent mean ± standard deviation of at least three independent replicates. b-c-d Western-blot analysis of cyclin A, cyclin E, p53 and p21 upon treatments with BRV or LCM at IC20 in T98G a U87MG b SW1783 c cells. e Transwell migration assay in U87MG cells upon BRV or LCM treatments. (IC20). f Western-blot analysis of EGFR and N-cadherin proteins expression levels in U87MG cells upon BRV or LCM treatments (IC20)